Publications by authors named "Tetsurou Honda"
Article Synopsis
- PIVKA-II is a marker used to diagnose hepatoma (liver cancer) but can also appear in patients without liver issues.
- A study analyzed the relationship between serum PIVKA-II levels and various clinical measurements of bone and muscle health in 441 patients with liver disease.
- Results indicated that high PIVKA-II levels were linked to serious liver disease, abnormal bone health in women, and muscle weakness in men, suggesting that monitoring PIVKA-II might help manage bone and muscle health in these patients.
Article Synopsis
- - Hepatic osteodystrophy (HOD) is a frequent issue in patients with chronic liver diseases like hepatitis C, leading to osteoporosis and bone density loss.
- - A study involving 78 patients treated with direct-acting antivirals (DAA) showed that while HCV was successfully treated, the impact on bone metabolic markers and bone density was varied between genders; males had a decrease in undercarboxylated osteocalcin (ucOC) while females did not.
- - Overall, DAA treatment appears to improve ucOC levels in male patients and influences vitamin K status, suggesting potential benefits for bone health in individuals with HOD related to chronic liver disease.
Article Synopsis
- - Hepatitis B virus (HBV) can lead to osteoporosis and loss of bone mineral density (BMD), but treatment with Tenofovir alafenamide (TAF) results in less BMD loss compared to another medication, Tenofovir disoproxil.
- - A study involving 87 HBV patients treated with TAF found that after one year, levels of TRACP-5b (a bone metabolism marker) decreased, indicating potential benefits in bone health.
- - The research suggests that switching to TAF may improve BMD in patients previously treated with Entecavir, with TAF possibly helping to prevent fractures due to its effect on bone metabolism.
Article Synopsis
- A study aimed to evaluate the effectiveness of the SARC-F questionnaire and calculated body muscle mass (CBMM) for identifying sarcopenia in patients with chronic liver disease.
- The analysis included 482 patients who underwent various assessments, revealing that the cutoff values for sarcopenia were <27.903 for females and <39.731 for males in CBMM and a SARC-F score of ≥4 points.
- The modified SARC-F questionnaire that combined elements from the original SARC-F, CBMM, gender, and age showed improved screening accuracy over both SARC-F and CBMM alone.
Article Synopsis
- Patient-reported outcomes (PROs) are crucial for assessing the quality of life (QOL) and symptoms in hepatitis C patients, evaluated at the start and three years after direct-acting antiviral (DAA) treatment.
- The study found that improvements in general health perception (GHN) were associated with better sleep quality and increases in muscle mass over three years.
- Results indicate that enhanced muscle volume post-treatment correlates with improved QOL, highlighting that sleep disturbances and other symptoms are interconnected with overall health outcomes.
Article Synopsis
- Sarcopenia, a condition characterized by loss of muscle mass in patients with chronic liver disease, can be assessed using inexpensive screening methods like the sarcopenia index (SI) and calculated body muscle mass (CBMM).
- A study evaluated these methods on 303 liver-damaged patients, comparing the results with traditional measures like grip strength and muscle mass determined through CT imaging.
- The findings revealed strong correlations between CBMM, SI, and muscle-related metrics, suggesting that low levels of these indices effectively indicate the presence of sarcopenia, particularly in both men and women.
Article Synopsis
- - The study found that the serum creatinine-based glomerular filtration rate (CrGFR) often overestimates kidney function in patients with liver disease, and explored differences between CrGFR and cystatin C GFR (dGFR).
- - Researchers evaluated several factors in 313 liver-damaged patients, including muscle mass and strength, using various scores and biomarkers like the sarcopenia index (SI) and calculated body muscle mass (CBMM).
- - Results showed that both CBMM and SI are strongly correlated with muscle mass and strength, indicating their significance in assessing sarcopenia in liver disease patients; dGFR was also found to be a reliable marker for liver damage and muscle strength, independent
The present study evaluated the changes in lipid profile, and the associations between serum protein convertase subtilisin/kexin 9 (PCSK9), microRNA (miR)122 and low-density lipoprotein variation following treatment of hepatitis C virus (HCV) genotype 1b infection with Daclatasvir/Asunaprevir. A total of 39 patients with HCV genotype 1b infection with chronic hepatitis received a 24-week treatment regimen of Daclatasvir/Asunaprevir. Laboratory data were obtained for each subject every 4 weeks during treatment and every 12 weeks after treatment.
View Article and Find Full Text PDFObjective Direct-acting antivirals (DAAs) for treating hepatitis C virus (HCV) infection exert a significantly high sustained viral response (SVR), and patients experience a rebound increase in low-density lipoprotein cholesterol (LDL) and total cholesterol levels. Carotid intima-media thickness (IMT) is a highly reproducible and non-invasive parameter for assessing the atherosclerotic process, and the small dense (sd) LDL level is useful for clinically evaluating the atherogenic risk. Methods A total of 48 patients with chronic HCV infection were treated with DAAs.
View Article and Find Full Text PDFAim: Direct-acting antivirals (DAAs) for the treatment of hepatitis C virus (HCV) infection have a significantly high sustained virologic response rate after a short treatment course and do not have any severe adverse effects. Patient-reported outcomes (PROs) have become increasingly important to assess the total impact of a chronic disease. We aimed to evaluate the changes in symptoms of patients with HCV infection treated with DAAs by using PROs.
View Article and Find Full Text PDF